Combining psychotherapy and pharmacotherapy — structured clinical viva

Markers want a consultant-level account of combination as strategy (not failure, not dogma), sequential residual-symptom psychotherapy after pharmacologic response, durability of CT skills versus medication discontinuation risk, maintenance needs in recurrent depression, and plain-language explanation without anti-medication or anti-therapy ideology.[1][3][4]

Structured psychotherapy plus psychotropic medication in one episode of care — concurrent, sequential, or collaborative/integrated packages. Not meds plus unstructured chat. Intent may be acute efficacy, residual symptoms, relapse prevention, or adherence support.[1][6]

No. Many patients benefit from either modality alone; combination is often additive, especially versus medication alone, and network evidence supports superiority of combination over monotherapies in adult depression. Partial response with residual symptoms is a reason to add therapy, not a personal failure.[1][6]

CT can match medications for initial treatment of moderate–severe MDD when competently delivered.[2] After response, discontinuing medication risks more relapse than after CT when active treatments stop — skills confer durability; this is not an instruction to stop her SSRI today without a plan.[3]

She has remitted on escitalopram but residual anhedonia/avoidance and relapse fear. Guidi–Fava sequential model: after pharmacologic response, add psychotherapy targeting residual symptoms and well-being/relapse prevention rather than automatic polypharmacy.[4] Behavioural activation, cognitive relapse-prevention, and interpersonal work fit.

Not automatically. Recurrent depression (three episodes) often warrants maintenance pharmacotherapy for a substantial period; classic Frank maintenance data underscore full-dose maintenance antidepressant value in highly recurrent illness, with IPT maintenance intermediate.[5] Decision is shared: episode count, residual symptoms, prior relapse on stop, preference, pregnancy plans. If later taper is chosen, do it planned with booster therapy and early-warning signs — not abrupt stop because CBT begins.

No mechanistic prohibition. Tablets reduce intensity; therapy trains skills. Meta-analyses support adding psychotherapy to antidepressants.[1] Explain complementary roles; agree who manages side effects and crisis; keep measures shared.

False dichotomy; pseudo-CBT; stopping indicated meds for ideology; ignoring residual symptoms after scale “remission”; split care without communication; benzodiazepine safety behaviours in anxiety pathways (if relevant later).[1][4]